200 related articles for article (PubMed ID: 24578240)
1. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Coleman RE
J Nucl Med; 2014 Apr; 55(4):574-81. PubMed ID: 24578240
[TBL] [Abstract][Full Text] [Related]
2. Impact of (18)F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Quinn B; Coleman RE
J Nucl Med; 2014 Jul; 55(7):1054-61. PubMed ID: 24819422
[TBL] [Abstract][Full Text] [Related]
3. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Quinn B; Shields AF
J Nucl Med; 2015 Feb; 56(2):222-8. PubMed ID: 25593113
[TBL] [Abstract][Full Text] [Related]
4. Intended Versus Inferred Treatment After
Hillner BE; Hanna L; Makineni R; Duan F; Shields AF; Subramaniam RM; Gareen I; Siegel BA
J Nucl Med; 2018 Mar; 59(3):421-426. PubMed ID: 29191854
[TBL] [Abstract][Full Text] [Related]
5. Hospice Admission and Survival After
Gareen IF; Hillner BE; Hanna L; Makineni R; Duan F; Shields AF; Subramaniam RM; Siegel BA
J Nucl Med; 2018 Mar; 59(3):427-433. PubMed ID: 29284672
[TBL] [Abstract][Full Text] [Related]
6. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Liu D; Shields AF; Gareen IF; Hanna L; Stine SH; Coleman RE
J Clin Oncol; 2008 May; 26(13):2155-61. PubMed ID: 18362365
[TBL] [Abstract][Full Text] [Related]
7. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
8. Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts.
Hillner BE; Siegel BA; Hanna L; Shields AF; Duan F; Gareen IF; Quinn B; Coleman RE
J Nucl Med; 2012 May; 53(5):831-7. PubMed ID: 22448033
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.
Jadvar H; Desai B; Ji L; Conti PS; Dorff TB; Groshen SG; Gross ME; Pinski JK; Quinn DI
Clin Nucl Med; 2012 Jul; 37(7):637-43. PubMed ID: 22691503
[TBL] [Abstract][Full Text] [Related]
10. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry.
Hillner BE; Siegel BA; Shields AF; Liu D; Gareen IF; Hunt E; Coleman RE
J Nucl Med; 2008 Dec; 49(12):1928-35. PubMed ID: 18997054
[TBL] [Abstract][Full Text] [Related]
11. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F-NaF and ¹⁸F-FDG Administration for PET/CT Imaging.
Minamimoto R; Mosci C; Jamali M; Barkhodari A; Habte F; Jackson T; Mittra E; Gambhir SS; Iagaru A
J Nucl Med; 2015 May; 56(5):688-94. PubMed ID: 25840978
[TBL] [Abstract][Full Text] [Related]
12. Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer.
Simoncic U; Perlman S; Liu G; Jeraj R
Nucl Med Commun; 2015 Dec; 36(12):1174-80. PubMed ID: 26378490
[TBL] [Abstract][Full Text] [Related]
13. Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone.
Sampath SC; Sampath SC; Mosci C; Lutz AM; Willmann JK; Mittra ES; Gambhir SS; Iagaru A
Clin Nucl Med; 2015 Mar; 40(3):e173-7. PubMed ID: 25140557
[TBL] [Abstract][Full Text] [Related]
14. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
[TBL] [Abstract][Full Text] [Related]
15. The National Oncologic PET Registry (NOPR): design and analysis plan.
Hillner BE; Liu D; Coleman RE; Shields AF; Gareen IF; Hanna L; Stine SH; Siegel BA
J Nucl Med; 2007 Nov; 48(11):1901-8. PubMed ID: 17942807
[TBL] [Abstract][Full Text] [Related]
16. Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy.
Lin FI; Rao JE; Mittra ES; Nallapareddy K; Chengapa A; Dick DW; Gambhir SS; Iagaru A
Eur J Nucl Med Mol Imaging; 2012 Feb; 39(2):262-70. PubMed ID: 22065013
[TBL] [Abstract][Full Text] [Related]
17. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
[TBL] [Abstract][Full Text] [Related]
18. Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.
Subramaniam RM; Shields AF; Sachedina A; Hanna L; Duan F; Siegel BA; Hillner BE
Oncologist; 2016 Sep; 21(9):1079-84. PubMed ID: 27401896
[TBL] [Abstract][Full Text] [Related]
19. Prospective comparative study of
Fonager RF; Zacho HD; Langkilde NC; Fledelius J; Ejlersen JA; Hendel HW; Haarmark C; Moe M; Mortensen JC; Jochumsen MR; Petersen LJ
Acta Oncol; 2018 Aug; 57(8):1063-1069. PubMed ID: 29447047
[TBL] [Abstract][Full Text] [Related]
20. Combined 18F-NaF and 18F-FDG PET/CT in the Evaluation of Sarcoma Patients.
Jackson T; Mosci C; von Eyben R; Mittra E; Ganjoo K; Biswal S; Gambhir SS; Iagaru A
Clin Nucl Med; 2015 Sep; 40(9):720-4. PubMed ID: 26053718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
